Outcome of COPD patients with mild daytime hypoxaemia with or without sleep-related oxygen desaturation


ABSTRACT: The aim of the present study was to compare the evolution of pulmonary haemodynamics and of arterial blood gases in chronic obstructive pulmonary disease (COPD) patients with mild-to-moderate hypoxaemia, with or without sleep-related oxygen desaturation.

COPD patients with daytime arterial oxygen partial pressure in the range 56–69 mmHg were included prospectively. Sleep-related oxygen desaturation was defined as spending ≥30% of the nocturnal recording time with arterial oxygen saturation <90%.

From the 64 patients included, 35 were desaturators (group 1) and 29 were nondesaturators (group 2). At baseline (t0), patients with sleep-related desaturation had a significantly higher daytime (mean ± SD) arterial carbon dioxide partial pressure (Paco2) (44.9 ± 4.9 mmHg versus 41.0 ± 4.1 mmHg, p = 0.001) whereas mean pulmonary artery pressure (mPAP) was similar in the two groups. After 2 yrs (t2) of follow-up, 22 desaturators and 14 nondesaturators could be re-evaluated, including pulmonary haemodynamic measurements. None of the nondesaturator patients became desaturators at t2. The difference between the two groups in terms of daytime Paco2 was still present at t2. The mean changes in mPAP from t0 to t2 were similar between the two groups, as were the rates of death or requirement for long-term oxygen therapy (American Thoracic Society criteria) during follow-up of up to 6 yrs.

The presence of sleep-related oxygen desaturation is not a transitional state before the worsening of daytime arterial blood gases, but is a characteristic of some chronic obstructive pulmonary disease patients who have a higher daytime arterial carbon dioxide partial pressure. Such isolated nocturnal hypoxaemia or sleep-related worsening of moderate daytime hypoxaemia does not appear to favour the development of pulmonary hypertension, nor to lead to worsening of daytime blood gases.


Patients with severe hypoxaemia due to chronic obstructive pulmonary disease (COPD) become more hypoxaemic during sleep [1]. Such sleep-related oxygen desaturation occurs mainly, but not exclusively, during rapid eye movement sleep [2, 3]. The suspected deleterious effects of this worsening of hypoxaemia during sleep include increased mortality at night, polycythaemia [4] and poor sleep quality [5]. Reduced oxygen saturation (SaO2) during sleep leads to a concomitant rise of mean pulmonary artery pressure (mPAP) [6, 7]. However, these observations have been made in patients with marked daytime hypoxaemia (arterial oxygen partial pressure (PaO2) <55 mmHg). Consequently, the specific effect of worsening of hypoxaemia during sleep is difficult to assess. Whatever the specific role of sleep-related oxygen desaturation in severely hypoxic COPD patients, such individuals are usually treated with long-term oxygen therapy (LTOT) according to usual criteria [8, 9]. Since such home oxygen therapy inevitably includes sleep time, their sleep-related hypoxaemia is corrected [10].

COPD patients with less severe daytime hypoxae- mia (PaO2 >55 mmHg) do not qualify for LTOT. Several groups [11–13] have observed that these patients frequently have nocturnal desaturation, which raises the question: does isolated nocturnal hypoxaemia or worsening of mild daytime hypoxae- mia during sleep account for an increased morbidity and mortality in COPD patients? In fact, only a few studies have addressed this question [11–15]. Since oxygen therapy could be prescribed in these patients, the course of the disease could be altered and life expectancy improved if it was clear that isolated sleep-related desaturation was indeed deleterious. Conversely, if sleep-related hypoxaemia has no effect on the outcome of the disease, prescription of oxygen during sleep would be a waste of medical resources.

To answer this question, this study prospectively investigated 118 COPD patients. Seventy-six patients
were included in a randomized trial of nocturnal oxygen therapy recently published [16]. Of these, 41 were allocated to nocturnal oxygen therapy and 35 to no nocturnal oxygen therapy. The aim of the present study was to compare the 35 patients with nocturnal desaturation not treated with oxygen therapy in the trial quoted above [16] to 29 otherwise comparable patients, but without nocturnal oxygen desaturation (fig. 1). All the patients were recruited prospectively during the same period of time in a stable state of the disease. The end-points were the change in pulmonary haemodynamics after 2 yrs of follow-up and the evolution of respiratory failure. Survival status of the 64 patients was also assessed.

Patients and methods

The eligible population consisted of patients who fulfilled the following criteria: 1) a diagnosis of COPD based on usual clinical and functional criteria (the forced expiratory volume in one second/vital capacity (FEV1/VC) ratio had to be <60% and the total lung capacity had to be >80% of the predicted value [17], in order to exclude restrictive diseases); 2) the presence of mild-to-moderate daytime hypoxaemia, with a daytime PaO2 in the range 56–69 mmHg on two measurements separated by 4 weeks, in patients free of acute exacerbation and in a stable state of the disease. Arterial carbon dioxide partial pressure (PaCO2) could be high (≥45 mmHg) normal or low (≤36 mmHg). Arterial blood gases were drawn from the patient whilst breathing ambient air, in the morning, after a 15-min resting period in the supine position; and 3) agreement to undergo right heart catheterization, full night polysomnography and to be followed-up once every 6 months during at least 2 yrs.

The great majority of patients were exsmokers. Current smokers were strongly advised to stop smoking. Patients who were unable to stop smoking were not included. Patients were also excluded if they had left heart or congenital heart disease, coexistent lung diseases such as interstitial lung diseases, bronchiectasis, lung carcinoma, or other severe diseases that could influence survival (hepatic cirrhosis, chronic renal failure). In addition, patients were excluded if they had obstructive sleep apnoea syndrome, defined by an apnoea/hypopnoea index ≥10 events·h⁻¹. Patients receiving oxygen therapy, even limited to sleep or exercise, or treated with almitrine bimesylate or other respiratory analeptics were also excluded.

The study protocol was approved by the Ethics Committee of the University Hospital of Strasbourg (France). Between June 1992 and February 1996, 118 patients were recruited from 6 hospital outpatient clinics of 5 European countries. One-hundred and five patients met the study criteria and gave informed consent. Forty-one patients received nocturnal oxygen therapy as part of a randomized trial already published [16] and, therefore, were excluded from the present study. From the remaining 64 patients (fig. 1), 35 were desaturators, defined by spending >30% of the nocturnal recording time (time in bed) with a transcutaneous SaO2 <90% (i.e. SaO2<90%) [12]. These 35 patients formed group 1. The remaining 29 patients formed group 2 (nondesaturators); by definition they spent <30% of the night with an SaO2 <90%. Examples of nocturnal oximetric recordings, one in a desaturator patient and another in a non-desaturator patient, are shown in figure 2.

Baseline assessment

Pulmonary volumes were measured by conventional spirometry by the helium-dilution method. Reference values were those of the European Respiratory Society [17].

Right heart catheterization was performed as reported previously [18] in all patients at baseline. Briefly, patients were investigated in the supine position, in the morning, after a light breakfast. Either balloon-tipped Swan-Ganz catheters or small Grandjean floating catheters were introduced percutaneously. Systolic, diastolic and mean pressures were averaged over five respiratory cycles. The zero reference was at mid-thoracic level. A catheter was introduced into the radial artery for measurement of arterial blood gas tensions. Cardiac output was calculated according to the Fick principle applied to oxygen, measurements being obtained during the last min of a 15-min resting period.

In order to firstly exclude the presence of obstructive sleep apnoea and secondly, to determine if the patient did or did not have sleep-related oxygen desaturation, all patients underwent conventional polysomnography, performed as reported previously [13]. Standard techniques, including electroencephalogram (C4/A1;C3/A2), electro-oculogram and submental electromyogram were used. Nasal and oral airflows were detected by thermistors. Rib cage and abdominal movements were detected using pneumobelts. SaO2 was recorded continuously with a pulse oximeter. The baseline SaO2 was measured with the subject awake, in

![Fig. 1. – Study profile. OSAS: obstructive sleep apnoea syndrome; NOT: nocturnal oxygen therapy.](image-url)
the supine position during the 30 min preceding the onset of sleep. The mean nocturnal SaO₂ and tSaO₂ <90% were calculated by computer software.

All patients underwent two oximetric studies at baseline (t0); the first involved simple all-night oximetry. The second, separated from the first study by ≤2 weeks, was combined with polysomnography. This was performed in both instances with the same apparatus (model 3740; Ohmeda, Englewood, CO, USA) using a finger probe. The waveforms of all oximetric studies were assessed at the beginning and at the end of the recording. Comparison of the two oximetric recordings at t0 in individual patients showed similar results. The results, given in tables 1, 2 and 3, are those of the second oximetry.

Follow-up and end-points

Patients were followed-up regularly, once every 6 months, with the measurement of arterial blood gases while breathing room air. Patients whose daytime PaO₂ fell persistently below 55 mmHg during the follow-up (at least two controls of arterial blood gases separated by a minimum of 1 month and not performed during an acute exacerbation of the disease) were given conventional LTOT (≥18 h·day⁻¹). This was the only way of prescribing oxygen therapy during the entire follow-up of the present study. Information on survival and requirement of LTOT of the 64 patients was collected until June 1, 1998, corresponding to a survival and requirement of LTOT of the 64 patients.

Statistical analysis

The Statistical Package for the Social Sciences (SPSS) computer software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. All variables except cardiac output, tSaO₂ <80% and lowest nocturnal SaO₂ (SaO₂ min) were distributed normally. Unless indicated, all data are expressed as mean ± SD. The proportions were compared using Chi-squared test or Fisher’s exact test when the former was not valid. Comparisons of continuous variables between groups of patients were performed with t-test for unpaired data or with the Mann-Whitney U-test for non-normally distributed variables. Changes in the anthropometric, spirometric, gasometric and pulmonary haemodynamic variables from t0 to t2 were assessed using paired t-test or, as appropriate, the Wilcoxon rank sum test. Correlations in univariate

Table 1. – Baseline (t0) mean ± SD, median and range values in the 64 patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean ± SD</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age yrs</td>
<td>64.6 ± 8.1</td>
<td>63.6</td>
<td>38.7–79.1</td>
</tr>
<tr>
<td>BMI kg·m⁻²</td>
<td>26.6 ± 5.2</td>
<td>25.8</td>
<td>17.0–37.1</td>
</tr>
<tr>
<td>VC % pred</td>
<td>77.0 ± 17.3</td>
<td>78.5</td>
<td>33.5–112.0</td>
</tr>
<tr>
<td>FEV₁ % pred</td>
<td>35.4 ± 11.1</td>
<td>34.9</td>
<td>16.2–67.6</td>
</tr>
<tr>
<td>TLC % of pred</td>
<td>108.4 ± 20.1</td>
<td>106.8</td>
<td>80.4–154.7</td>
</tr>
<tr>
<td>PaO₂ mmHg</td>
<td>63.4 ± 3.1</td>
<td>62.9</td>
<td>58–69</td>
</tr>
<tr>
<td>PaCO₂ mmHg</td>
<td>43.1 ± 5.0</td>
<td>43.0</td>
<td>34.9–54.9</td>
</tr>
<tr>
<td>mPAP rest mmHg</td>
<td>19.0 ± 4.9</td>
<td>18.0</td>
<td>11.0–32.0</td>
</tr>
<tr>
<td>PWP mmHg</td>
<td>8.4 ± 3.4</td>
<td>8.0</td>
<td>3.0–19</td>
</tr>
<tr>
<td>Cardiac output L·min⁻¹·m⁻²</td>
<td>3.01 ± 0.79</td>
<td>2.8</td>
<td>2.03–6.00</td>
</tr>
<tr>
<td>TST min</td>
<td>313 ± 86</td>
<td>325</td>
<td>181–480</td>
</tr>
<tr>
<td>REM %</td>
<td>14 ± 6</td>
<td>14</td>
<td>2.5–30</td>
</tr>
<tr>
<td>Mean nocturnal SaO₂ %</td>
<td>89.6 ± 3.3</td>
<td>90.0</td>
<td>74–95</td>
</tr>
<tr>
<td>tSaO₂ &lt;90% %</td>
<td>41.7 ± 36.2</td>
<td>34.0</td>
<td>1.0–100</td>
</tr>
<tr>
<td>tSaO₂ &lt;80% %</td>
<td>3.1 ± 13.0</td>
<td>0</td>
<td>0–36.3</td>
</tr>
<tr>
<td>SaO₂ min %</td>
<td>77 ± 12</td>
<td>82</td>
<td>45–91</td>
</tr>
</tbody>
</table>

BMI: body mass index; VC: vital capacity; FEV₁: forced expiratory in one second; TLC: total lung capacity; PaO₂: arterial oxygen partial pressure; PaCO₂: arterial carbon dioxide partial pressure; mPAP: mean pulmonary artery pressure; PWP: pulmonary "capillary" wedge pressure; TST: total sleep time; REM: rapid eye movement sleep time as a percentage of TST; SaO₂: arterial oxygen saturation; tSaO₂ <90% (80%): percentage of recording time spent with an SaO₂ <90% (80%); SaO₂ min: lowest nocturnal SaO₂.
analysis were assessed using Pearson’s method. Survival rates were determined according to the Kaplan-Meier method. To test the equality of survival rates between desaturators and nondesaturators, Log rank tests were used. All significance tests were two-tailed with a p-value < 0.05 indicating a statistical difference.

## Results

### Baseline data

Baseline data (at t0) of the group as a whole and the comparison between the two groups of patients (desaturators versus nondesaturators) are shown in tables 1 and 2. According to the lung function criteria, all patients had moderate or severe airway obstruction and mild or moderate daytime hypoxaemia. The mean PaO2 of the group as a whole was 63.4 ± 3.1 mmHg (range 58–69 mmHg). Only 5 of the 64 patients had a PaO2 < 60 mmHg. Apart from nocturnal oximetric data (by definition) and body mass index (BMI), the only significant difference observed between the two groups was a higher daytime PaCO2 in group 1 (desaturators) compared to group 2 (44.9 ± 4.9 mmHg versus 41.0 ± 4.1 mmHg; p = 0.001). Twenty-two of the 64 patients were hypercapnic (PaCO2 ≥ 45 mmHg) at t0; of these, 18 belonged to group 1 and 4 belonged to group 2 (51% versus 14%, respectively; p = 0.002). mPAP was similar in the two groups (19.5 ± 3.2 mmHg in group 1 versus 18.3 ± 4.3 mmHg in group 2, p = 0.34). Patients with mPAP ≥ 20 mmHg, defined as having pulmonary hypertension were 16/35 (46%) in group 1 and 10/29 (34%) in group 2 (p = 0.45). Consistent with the results of these comparisons of means between the two groups (table 2), tSaO2 < 90% which characterized nocturnal oxygenation, was correlated with BMI (r = 0.30, p = 0.016) and PaCO2 (r = 0.46, p < 0.001), whereas no significant correlation was observed between tSaO2 < 90% and mPAP (r = 0.15, p = 0.24).

### 2-yr re-evaluation

From the 35 patients of group 1, 22 could be re-evaluated after a mean follow-up of 25.5 ± 2.1 months (range 23.4–29.8 months; table 3). Similarly, from the 29 patients of group 2, 14 could be re-evaluated after a mean follow-up of 26.0 ± 2.0 months (range 22.7–28.6 months). The rates of death and of requirement of LTOT were similar in the two groups (see later) as well as the number of patients who refused the second right heart catheterization or were lost to follow-up before the 2-yr re-evaluation (nonsignificant difference with Fisher’s exact test). The comparisons of t0 versus
t2 values are shown in table 4. The authors found no change from t0 to t2 in any variable. In particular, no changes were observed in the pulmonary haemodynamic data. The mean changes in mPAP from t0 to t2 were +0.8 ± 4.8 mmHg in group 1 and +0.7 ± 3.0 mmHg in group 2 (p > 0.5). This study assumed that a difference of 4 mmHg between the two groups in terms of mPAP would have a clinical meaning. Consequently, the standard deviation of this variable being 5 mmHg, 22 and 14 patients in each group gave a power of 80% for this comparison.

All differences observed at t0 between groups 1 and 2 were found again at t2. Desaturator patients still had a significantly higher daytime PaCO2 than non-desaturator patients (44.8 ± 5.6 mmHg versus 41.0 ± 4.1 mmHg, p < 0.05). It was also observed that no patient from the non-desaturator group, as previously defined, had become a desaturator at t2, according to the same definition. Only two patients of the desaturator group (with tSaO2 < 90% of 40% and 30% at t0) became non-desaturators at t2.

**Survival and requirement of long-term oxygen therapy**

From the survival analysis, 16 patients were excluded (10 from group 1 and 6 from group 2) who were prescribed LTOT at any time during the entire follow-up (from June 1992 to June 1998). Indeed, the consequence of sleep-related oxygen desaturation on survival could not be determined when patients were receiving LTOT. Of the remaining 48 patients, nine died (fig. 3a). Four deaths occurred in the 25 patients of group 1 and 5 in the 23 patients of group 2 (p = 0.06 by the log rank test).

Finally, this study compared the first event, death or requirement of LTOT, which occurred in each of the 64 patients until June 1, 1998 (fig. 3b). The rates of absence of such events were similar in the two groups (p = 0.93 by the log rank test), with 14 events being observed in group 1 and 11 in group 2.

**Table 4. — Lung function, arterial blood gases and pulmonary haemodynamic data changes from baseline (t0) to 2-yr follow-up (t2)**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Desaturators Group 1</th>
<th>Non-desaturators Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subjects n</strong></td>
<td>22</td>
<td>14</td>
</tr>
<tr>
<td>BMI kg·m⁻²</td>
<td>28.3 ± 4.5</td>
<td>29.4 ± 4.2</td>
</tr>
<tr>
<td>VC % of predicted</td>
<td>79.6 ± 19.0</td>
<td>81.5 ± 19.9</td>
</tr>
<tr>
<td>FEV1 % of predicted</td>
<td>36.2 ± 8.6</td>
<td>37.6 ± 11.6</td>
</tr>
<tr>
<td>FEV1/VC %</td>
<td>36.5 ± 9.7</td>
<td>35.9 ± 9.4</td>
</tr>
<tr>
<td>PaCO₂ mmHg</td>
<td>63.1 ± 2.8</td>
<td>64.2 ± 5.3</td>
</tr>
<tr>
<td>PaCO₂ mmHg</td>
<td>44.3 ± 4.2</td>
<td>44.8 ± 5.6</td>
</tr>
<tr>
<td>mPAP rest mmHg</td>
<td>19.8 ± 5.6</td>
<td>20.5 ± 6.5</td>
</tr>
<tr>
<td>Mean nocturnal SaO₂ %</td>
<td>88.6 ± 1.9</td>
<td>88.7 ± 2.3</td>
</tr>
<tr>
<td>tSaO₂ &lt; 90% %</td>
<td>66.0 ± 25.0</td>
<td>39.3 ± 29.7</td>
</tr>
</tbody>
</table>

BMI: body mass index; VC: vital capacity; FEV1: forced expiratory volume in one second; PaO₂: arterial oxygen partial pressure; PaCO₂: arterial carbon dioxide partial pressure; mPAP: mean pulmonary artery pressure; SaO₂: arterial oxygen saturation; tSaO₂: percentage of recording time spent with SaO₂ below 90%; Differences within each group between t0 and t2 were not statistically significant for any variable (paired t test or Wilcoxon rank sum test); *: p < 0.05 group 1 *versus* group 2; **: p < 0.01; ***: p < 0.001, comparison of t2 values between groups 1 and 2 (unpaired t-test).

![Fig. 3. – Kaplan-Meier curves for a) survival and for b) disease free. The risk of death was not significantly different (p = 0.46 by the Log rank test) in the desaturators (-----) compared with the non-desaturators patients (—). Similarly the risk of death or worsening of respiratory failure assessed by the requirement of long-term oxygen therapy, corresponding to “absence of events” was not significantly different (p = 0.93 by the Log rank test) between the two groups.](image-url)

**Discussion**

To the authors’ knowledge, the present study is the first prospective study comparing the outcome of...
COPD patients with mild daytime hypoxaemia with and without sleep-related oxygen desaturation. The major findings are: 1) in such patients, sleep-related desaturation is seen particularly in those with a higher daytime $P_aCO_2; 2)$ changes in mPAP after 2 yrs of follow-up are unaffected by sleep-related oxygen desaturation; and 3) worsening of oxygenation during the night probably has no prognostic implication in COPD patients when daytime hypoxaemia is mild-to-moderate, but the small number of deaths precludes a more definitive conclusion.

All patients in the present study were recruited from respiratory clinics in a prospective fashion and were remote from any acute exacerbation of the disease. It was necessary to exclude 41 of the original 76 desaturator patients (fig. 1) since they received nocturnal oxygen therapy as part of a previously published randomized trial [16] and the aim of the present study was assessment of the consequences of sleep-related hypoxaemia. This exclusion of some patients could have introduced a bias in the comparison of desaturators and nondesaturators. However, it was believed that this was unlikely for two reasons. Firstly, exclusion was made after a randomization procedure in which the ensuing two groups were similar in all variables collected at baseline [16]; Secondly, the follow-up of desaturators and nondesaturators in the present study was performed in a similar way. The present study also checked that the 36 patients included from the coordinating centre did not differ from the other 28 patients concerning all variables listed in table 1 (data not shown). Thus, it is reasonable to assume that the present series of 64 patients is representative of COPD patients with mild-to-moderate daytime hypoxaemia who either do or do not show sleep-related oxygen desaturation.

To assess the relative role of nocturnal versus daytime hypoxaemia in inducing pulmonary haemodynamic and clinical differences and also for ethical reasons, it was necessary to choose a narrow range of daytime $P_aO_2$. Daytime $P_aO_2$ had to be 56–69 mmHg. In fact, most patients in the present study (42/64) had a $P_aO_2$ between 60–65 mmHg. In such a homogenous population of COPD patients, in terms of arterial blood gases, nocturnal desaturation could be totally absent or, conversely, almost permanent during sleep. Indeed, some patients of the present study spent all night with an $SaO_2>90\%$, whereas others had values always <90\% during sleep, spent 30–90 min with a nocturnal $SaO_2<85\%$ or had minimum values of nocturnal $SaO_2$ as low as 65–70\%.

All intermediary states were observed in the 64 patients. Thus, a cut-off value of 30\% of time spent with a nocturnal $SaO_2<90\%$ appears to be appropriate for classification of the patients. As confirmation, mean nocturnal $SaO_2$, $tSaO_2<80\%$ and the lowest nocturnal $SaO_2$ were all statistically different ($p<0.001$) between the two groups. If a less strict definition of sleep-related hypoxaemia such as that of FLETCHER et al. [14] was applied to the present series of patients, the number of nondesaturators would be too small to compare them to desaturators. It must also be emphasized that several groups [12, 15, 19] have observed very similar mean nocturnal $SaO_2$ when compared to those of the present study (~88\% in desaturators and ~92\% in nondesaturators).

The 35 patients with nocturnal desaturation were more hypercapnic during the day. Even though mean values of daytime $P_aCO_2$ in the two groups were in the normal range, individual values showed that 22 patients in all had a $P_aCO_2>45$ mmHg. Of these 22 patients, 18 and 4 were in the desaturator and nondesaturator groups, respectively ($p=0.002$ Fisher’s exact test). Several studies [11, 20, 21, 22] have found that patients with hypercapnia whilst awake are more likely to exhibit nocturnal oxygen desaturation. The present study also demonstrates that this difference in daytime $P_aCO_2$ between desaturators and nondesaturators persists over a period of 2 yrs. All nondesaturators remained nondesaturators and 20 of the 22 desaturator patients who could be re-evaluated remained desaturators. Since BMI was also higher at $t_0$ and $t_2$ in the desaturator group compared to the nondesaturator patients, it appears that most patients of the desaturator group were of the "blue bloated" type. Extrapolated to more severe COPD patients, this study’s results confirm that daytime $P_aCO_2$ is an important indicator of nocturnal hypoxaemia (mainly due to hypoventilation) which may be corrected by nocturnal, noninvasive ventilation [23].

One important end-point of the present study was the comparison of change ($t_2$ minus $t_0$ values) in mPAP between the two groups. Some of the 64 patients could not be re-evaluated. Nine patients of group 1 and 12 of group 2 died, refused the second right heart catheterization or were lost to follow-up. Unfortunately, this disadvantage of prospective longitudinal studies cannot be avoided. With regard to the four and three additional patients of groups 1 and 2, respectively, who required LTOT before the 2-yr re-evaluation, it cannot be excluded that due to the worsening of respiratory failure, pulmonary artery pressures might have increased significantly in these patients. Nevertheless, the number of patients who required LTOT over 2 yrs was small and equally distributed between the two groups, meaning it is unlikely that the inclusion of the measurements of mPAP of these seven patients would have modified the results.

The present data suggest that isolated nocturnal hypoxaemia does not induce permanent pulmonary hypertension, which is consistent with a previous cross-sectional report from a multicentric study group [13]. Two earlier studies [11, 12] have shown that patients with sleep-related oxygen desaturation have higher mPAP, but the differences were hardly significant and, more importantly, there was an important overlap of individual values between desaturators and nondesaturators in both studies. Furthermore, it must be kept in mind that the hypothesis that intermittent hypoxaemia could lead to pulmonary vascular remodelling, comes mainly from the observation that when correction of severe hypoxaemia is not continuous ($<24$ h $24$ h$^{-1}$ in COPD patients) there is no significant decrease in mPAP [24–26]. Indeed, the Nocturnal Oxygen Therapy Trial study [27] showed that in severely hypoxaemic ($P_aO_2<55$ mmHg) COPD
patients, mPAP and pulmonary vascular resistance decreased slightly but significantly only when oxygen therapy was "continuous" (>18 h·24 h^{-1}). However, this does not imply that the reverse proposal (intermittent hypoxaemia could lead to pulmonary hypertension) is true. In fact, it is now recognized that the development of pulmonary hypertension due to chronic alveolar hypoxia requires a certain threshold of severity and duration [28]. It is likely that this threshold was not reached during the episodes of nocturnal hypoxia in this study's desaturator patients.

An important issue is to know whether sleep-related oxygen desaturation in COPD patients with mild-to-moderate daytime hypoxaemia has prognostic implications. Fletcher et al. [15] reported that survival was significantly better in COPD patients without nocturnal desaturation. Unfortunately, that study was retrospective and such a design does not preclude an important bias. Mortality rates of desaturators and nondesaturators of the present study were not statistically different. Although prospective, the present survival analysis lacks the power to detect a difference due to the relatively small number of deaths. However, it must be emphasized that the present results were consistent with two recent studies [16, 29] on the effect of oxygen therapy in COPD patients with mild-to-moderate daytime hypoxaemia. In both studies [16, 29], the authors found no better survival in patients receiving oxygen therapy. When all the 105 patients of the present study who initially satisfied the inclusion criteria were examined in a survival analysis, only two covariates, BMI and FEV1, were associated with shorter survival (p < 0.05, data not shown). These latter results are also consistent with the study of Gorecka et al. [29].

Independently of the effect of sleep-related oxygen desaturation on survival, another important consequence might be impairment of health status as measured using quality of life questionnaires. Unfortunately, this study did not include such a questionnaire in the design of the present study and that question remains unanswered.

It is concluded that sleep-related oxygen desaturation is not a transitional state before diurnal worsening of arterial blood gases but is a feature characterizing some patients. Sleep-related oxygen desaturation is frequently associated with a higher daytime arterial carbon dioxide partial pressure. It does not favour the development of permanent pulmonary hypertension. The most important prognostic factors in chronic obstructive pulmonary disease patients are spirometric volumes and nutritional status and sleep-related oxygen desaturation does not appear to lead to worsening of daytime blood gases in patients with mild daytime hypoxaemia.

References

19. Vos PJ, Folgering HT, van Herwaarden CL. Predictors for nocturnal hypoxaemia (mean SaO2 < 90%) in


